--Study found variability in IgA levels in the bloodstream versus the gut, which may help explain why some with IgA deficiency have symptoms, while others do not--

PHILADELPHIA, May 26, 2023 /PRNewswire/ -- IgA deficiency is the most common primary immune deficiency worldwide, but its presentation has puzzled physcians and researchers. Some with the disorder present with symptoms like recurrent infections, autoimmune disease, or allergies, whereas others have no symptoms at all and only become aware of their IgA-deficient status through an incidental finding on a blood test. This variability has raised the question among researchers: Why aren't many of those with IgA deficiency sicker?

A new study by researchers at Children's Hospital of Philadelphia (CHOP) has begun to answer that question, demonstrating that IgA acts as a "tuner" that regulates the number of microbes the body sees every day, restraining the systemic immune response to these commensal microbes and limiting the development of systemic immune dysregulation.

"Right now, if we identify IgA deficiency in a patient through a blood test, we have no way of knowing whether the patient will become symptomatic if they aren't already, and we don't know whether or when they might go on to develop a more serious immune deficiency," said Sarah E. Henrickson, MD, PhD, an assistant professor and attending physician in the Division of Allergy and Immunology at CHOP and co-senior author of the paper, which was published today in Science Immunology. "Our paper lays the groundwork for being able to answer these critically important questions by providing a lens into how IgA and the microbiome interact and how an imbalance in that interaction could lead to symptomatic disease."

IgA (short for Immunoglobulin A) is an antibody protein that is part of the immune system and plays a role in fighting disease. It is found mainly in the respiratory and digestive tracts, but it can also be found in blood, saliva, tears, and breastmilk. To be diagnosed with IgA deficiency, patients must be over 4 years of age and have no IgA as determined through a blood test, as well as normal serum levels of IgG and IgM, without other known causes of immune deficiency.

More on TelAve News

• ScreenPoints Puts Film Investors in the Credits—and in the Money With New FinTech Platform
• Pathways to Adulthood Conference May 17 at Melville Marriott Honoring NYS Assembly Member Jodi Giglio, Suffolk County Legislator Nick Caracappa
• Adster Techologies awarded US Patent for breakthrough innovation in reducing latency in Ad Serving
• Robert Fabbio Inducted into the Austin Technology Council Hall of Fame
• Cybersecurity is Protecting Your Personal Information and Your Portfolio

Some researchers have suggested that perhaps IgM provides a "backup" role in some patients with IgA deficiency, explaining why some patients are asymptomatic. However, how secretory IgA and IgM work together in the mucosal system and whether their roles were redundant or distinct remained unclear.

To investigate this further, the researchers analyzed samples from 19 pediatric patients with IgA deficiency and 13 pediatric control patients, from 15 families, and they then complemented that analysis with studies of IgA deficient mice. They sought to answer two questions: how mucosal antibodies like IgA and IgM and system antibodies like IgG interact with mucosal microbes, and how IgA deficiency affects equilibrium of the immune system.

Analyzing both blood and fecal samples, the researchers measured antibody levels; identified the microbial targets of IgA, IgM, and IgG antibodies; and performed immune profiling to gauge the activation of the immune system. In doing so, they showed that although IgA, IgM and IgG target overlapping sets of microbes, the role of IgA is distinct from IgM in restraining commensal microbes in the gut, and IgM only modestly compensates for the absence of intestinal IgA.

They also determined that 26% of patients who were IgA deficient via blood tests had normal levels of IgA in their feces. Intriguingly, the patients with normal fecal IgA were less likely to develop immune dysregulation and clinical disease, as demonstrated through immune analysis of cytokine levels, whereas those deficient in both blood and fecal IgA were more likely to have elevated inflammatory cytokines and exhibit clinical symptoms.

To validate their findings, the researchers studied knockout mice who lacked IgA. Mirroring the findings in human patients, these mice exhibited elevated cytokines and immune dysregulation. The researchers also found live microbes in fat tissue of the knockout mice, which was not found in healthy control mice, providing further evidence for a role for IgA in modulating systemic microbial exposure.

"Based on these results, we propose that IgA supports the intestinal barrier to keep the proper balance of commensal microbes interacting with the immune system, acting as a tuner to keep the immune system in check," said co-senior author Michael Silverman, MD, PhD, an Assistant Professor and attending physician in the Division of Infectious Diseases at CHOP. "Without IgA protecting the gut, commensal bacteria can get through, increasing a patient's systemic exposure to these microbes and creating an inflammatory environment. Future studies with larger patient populations should investigate IgA levels in other target tissues and determine if these findings can be used to predict disease course and outcomes."

More on TelAve News

• L2 Aviation Celebrates Grand Opening of New Facility at Cincinnati/Northern Kentucky International Airport (CVG)
• Managing Summer Staffing Surges with Confidence: Why Name Badges Are a Must for Seasonal Success
• Visa Named Title Sponsor of Ascending Athletes' Business Owners Summits for NFL Entrepreneurs
• The Paris Court of International Arbitration Elects Dr. John J. Maalouf as its New President
• Whistleblower Seeks SEC and Shareholder Review of Cogent Communications' 2003 Acquisition of FNSI

Conrey et al. "IgA deficiency destabilizes immune homeostasis towards intestinal microbiota and increases the risk of systemic immune dysregulation," Science Immunology, May 26, 2023, DOI: 10.1126/sciimmunol.ade2335

About Children's Hospital of Philadelphia: A non-profit, charitable organization, Children's Hospital of Philadelphia was founded in 1855 as the nation's first pediatric hospital. Through its long-standing commitment to providing exceptional patient care, training new generations of pediatric healthcare professionals, and pioneering major research initiatives, the 595-bed hospital has fostered many discoveries that have benefited children worldwide. Its pediatric research program is among the largest in the country. The institution has a well-established history of providing advanced pediatric care close to home through its CHOP Care Network, which includes more than 50 primary care practices, specialty care and surgical centers, urgent care centers, and community hospital alliances throughout Pennsylvania and New Jersey, as well as an inpatient hospital with a dedicated pediatric emergency department in King of Prussia. In addition, its unique family-centered care and public service programs have brought Children's Hospital of Philadelphia recognition as a leading advocate for children and adolescents. For more information, visit https://www.chop.edu.

Contact: Amanda DiPaolo Bradley
Children's Hospital of Philadelphia
(267) 391-8599
[email protected]

SOURCE Children's Hospital of Philadelphia

---

Show All News | Report Violation